scholarly journals Recent childbirth is an adverse prognostic factor in breast cancer and melanoma, but not in Hodgkin lymphoma

2013 ◽  
Vol 49 (17) ◽  
pp. 3686-3693 ◽  
Author(s):  
Henrik Møller ◽  
Arnie Purushotham ◽  
Karen M. Linklater ◽  
Hans Garmo ◽  
Lars Holmberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Hodgkin Lymphoma ◽  
Adverse Prognostic Factor

Young age is not always an adverse prognostic factor in breast cancer

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 825-825 ◽  
Author(s):  
M. A. Seoud ◽  
M. Khalil ◽  
N. El- Saghir ◽  
Z. Salem ◽  
M. Charafeddine ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Young Age ◽  
Adverse Prognostic Factor

Young Age as an Independent Adverse Prognostic Factor in Premenopausal Patients with Breast Cancer

2002 ◽  
Vol 3 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Peter C. Dubsky ◽  
Michael F.X. Gnant ◽  
Susanne Taucher ◽  
Sebastian Roka ◽  
Daniela Kandioler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Young Age ◽  
Adverse Prognostic Factor ◽  
Premenopausal Patients ◽  
Independent Adverse Prognostic Factor

Association of body mass index and outcome in advanced breast cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1044-1044
Author(s):  
Claudia Andreetta ◽  
Pamela Driol ◽  
Marta Bonotto ◽  
Lorenzo Gerratana ◽  
Francesca Valent ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Prognostic Factor ◽  
Advanced Breast Cancer ◽  
Body Mass ◽  
Menopausal Status ◽  
Advanced Breast ◽  
Consecutive Series ◽  
First Line ◽  
Adverse Prognostic Factor

1044 Background: Obesity represents a well-known risk factor for the development of breast cancer and an adverse prognostic factor in early disease. Overweight is associated with reduced efficacy of aromatase inhibitors in adjuvant setting. Few data have been reported about the potential relationship of overweight and outcome in advanced breast cancer (ABC). Methods: We retrospectively evaluated body mass index (BMI) in a consecutive series of 400 ABC patients treated at our institution. BMI was calculated at baseline of diagnosis of ABC. We evaluated association of BMI and other prognostic and predictive markers with Progression Free Survival (PFS) and Overall Survival (OS). We evaluated PFS at first and subsequent lines of chemotherapy (CT) and endocrine therapy (ET). Overweight patients were defined as having BMI > 25. Results: Overweight patients were 52%. Median age of the population was 58 years. Median OS was 33.7 months. Overall, 76% of patients presented with ER+ and 17.7% with HER2+ ABC.Overweight was associated with increased age at diagnosis, menopausal status and luminal B or triple negative immunophenotype. At multivariate analysis, BMI > 25 was associated with better PFS at first-line ET (HR= 0.68, 95% CI 0.46-0.99). BMI was not associated with OS. Conclusions: BMI at baseline does not seem to be an adverse prognostic factor for ABC patients. Overweight may be associated with better PFS in endocrine responsive ABC treated with ET, especially in first-line setting. The role of BMI in ABC deserves to be further investigated.

scholarly journals Should a Bulky Mediastinal Mass ≥7cm in the Longest Dimension be Considered an Adverse Prognostic Factor in Patients with Advanced Hodgkin Lymphoma and Negative Interim PET/CT?

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4051-4051
Author(s):  
Eldad J Dann ◽  
Rebeca Lopez-Alonso ◽  
Shunan Qi ◽  
Tania Mashiach ◽  
Michal Weiler-Sagie ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Hodgkin Lymphoma ◽  
Mediastinal Mass ◽  
Reference Group ◽  
Free Survival ◽  
Adverse Prognostic Factor ◽  
Interim Pet ◽  
Mediastinal Masses ◽  
Pet Ct ◽  
Mass Size

Introduction: Nowadays, treatment decision making in advanced Hodgkin lymphoma (ad-HL) is based on pre-therapy risk factors and interim PET/CT (PET-2) results, used as a platform for therapy modification. In the past, a bulky mediastinal mass (BMM) was not found to be a significant risk factor and was not included in the final version of the International Prognostic Score (IPS) system (Hasenclever, NEJM 1998). The current study aimed to assess the effect of BMM presence on relapse-free survival (RFS) in patients (pts) with ad-HL and to determine the optimal cutoff of the mass size for outcome prediction in the PET/CT era. Methods: The Israeli Hodgkin Lymphoma Study Group selected to initiate therapy with standard BEACOPP (SB: bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) or ABVD (adriamycin, bleomycin, vinblastine, dacarbazine) in HL pts with IPS 0-2 and with intensified therapy using escalated BEACOPP (EB: bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in pts with IPS ≥3. Treatment was modified according to PET-2 results. To pts with negative PET-2 another 4 cycles of SB/ABVD were administered. PET-2 positive pts received 4 EB cycles followed by radiation therapy (Dann, Blood 2007). In the present study, disease bulkiness, assessed using baseline PET/CT, was retrospectively evaluated in a cohort of HL pts. The data included measurements of the longest diameter of either the biggest single mass or a conglomerate of lymph node masses in the transverse or coronal plane in the PET/CT image. Prognostic values of mediastinal mass cutoffs of ≥5 cm, ≥7 cm, >10 cm for RFS and progression-free survival (PFS) were compared. Results: One hundred and ninety six pts (female/male: 46/54%) with ad-HL [stage IIB - 28, stage III - 74, stage IV - 94; IPS 0-2 - 104; IPS 3-7 - 92; median age 31 years (16-85)] treated at the Rambam Health Care Campus (n=121) and Memorial Sloan Kettering Cancer Center (n=75) between 2000-2016 were included in the analysis. Mediastinal masses ≥5 cm, ≥7 cm and >10 cm were observed in 125 (63%), 82 (42%), 36 (18%) pts, respectively. PET-2 was negative in 79% of pts. At a median follow-up of 66.5 (1-222) months [80 (4-222) for pts without disease progression and 12 (1-62) for those with relapse or progression], estimated 5-year RFS and PFS for the entire group were 82% and 79%, respectively. A mass of up to 7 cm was found in 62 % of pts (n=123); 22% (n=44) had a mass measuring between 7 and 9.9 cm and 15% (n=29) had a mass ≥10 cm. Mediastinal masses were prevalent in 126/196 (64%) pts; in 58 (30%) of them the mediastinal mass, while being biggest, did not exceed 7 cm, and 68 (34%) had BMM of ≥7 cm. We found no effect of bulky disease, either mediastinal or non-mediastinal, on the outcome of the PET-2 positive group. Univariate analysis showed that in pts with negative PET-2, BMM ≥7 cm was a significant adverse prognostic factor for both 5-year RFS and PFS (HR 2.85; 95% CI 1.09-7.41; p=0.032 and HR 2.86; 95% CI 1.1-7.45; p=0.032, respectively). Outcome comparison of PET-2 negative pts with BMM (≥7 cm) to pts with negative PET-2 and either non-mediastinal or mediastinal non-bulky (<7cm) masses (reference group) revealed an inferior 5-year RFS of 73% versus 89% (HR 2.97; 95% CI 1.37-6.42; p=0.006) in the former group. Of note, both groups received an ABVD/SB regimen. HR for RFS was insignificant when a mass size cutoff of ≥5 cm or >10 cm was used. The HR for RFS was particularly high in the comparison between the subgroup of PET-2 negative pts with IPS 0-2 and BMM (≥7 cm) and those with IPS 0-2 in the reference group, demonstrating a 5-year RFS of 59% versus 89% with HR of 4.20 (95% CI 1.59-11.05; p=0.004). PET-2 negative pts with IPS 3-7 and BMM (≥7 cm) did not have an inferior outcome compared to pts with IPS 3-7 from the reference group (5-year RFS of 82% versus 89%). Notably, the two groups were treated with an EB-containing regimen. Our results indicate that BMM is an important adverse prognostic factor predominantly for pts with IPS 0-2. Multivariate Cox regression analysis identified BMM ≥7 cm as the most significant adverse prognostic factor for RFS (Table 1; Fig. 1). Conclusions: In PET-2 negative pts with ad-HL, mediastinal masses ≥7 cm in any plane are associated with the highest risk for HL progression. These findings should be incorporated in a new prognostic scoring system upon more extensive evaluation in a larger cohort. Disclosures No relevant conflicts of interest to declare.

scholarly journals Low number of examined lymph nodes in node-negative breast cancer patients is an adverse prognostic factor

2006 ◽  
Vol 17 (11) ◽  
pp. 1644-1649 ◽  
Author(s):  
I. Blancas ◽  
J.L. García-Puche ◽  
B. Bermejo ◽  
E.O. Hanrahan ◽  
C. Monteagudo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Lymph Nodes ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Adverse Prognostic Factor ◽  
Node Negative Breast Cancer

scholarly journals High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

2013 ◽  
Vol 108 (5) ◽  
pp. 1100-1105 ◽  
Author(s):  
F Zagouri ◽  
Z Bago-Horvath ◽  
F Rössler ◽  
A Brandstetter ◽  
R Bartsch ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Adverse Prognostic Factor

Expression of E26 transformation specific-1 (ETS-1) in tumour-infiltrating lymphocytes (TILs) is adverse prognostic factor in invasive breast cancer

2021 ◽  
pp. 1-7
Author(s):  
Velibor Puzovic ◽  
Jasminka Jakic-Razumovic
Keyword(s):  
Breast Cancer ◽  
Prognostic Factor ◽  
Invasive Breast Cancer ◽  
Histological Grade ◽  
Tumour Size ◽  
Disease Free Survival ◽  
Proliferation Index ◽  
Adverse Prognostic Factor ◽  
Tumour Infiltrating Lymphocytes ◽  
Infiltrating Lymphocytes

AIM OF THE STUDY: The microenvironment depicts the relationship between tumour cells and immune response, and every insight into stromal lymphocytes could contribute to explain their role and activity. E26 transformation specific-1 (ETS-1) is a transcription factor that is active in cell proliferation. We analysed its immunohistochemical expression in tumour infiltrating lymphocytes (TILs) in invasive breast cancer and correlated its immunohistochemical score (IHS) to traditional predictive and prognostic factors and survival. MATERIALS AND METHODS: The sample contains data of 121 patients with invasive breast cancer, not otherwise specified (NOS) who underwent mammectomy and lymphadenectomy in 2002 at the Clinical Hospital Centre Zagreb, Croatia. Paraffin blocks of the tumour tissue were collected from the pathological archive. Three representative areas of every patient were chosen and multiple tissue samples were made. Immunohistochemical staining with rabbit anti-ETS-1 (Novocastra, UK) and the ABC method was performed on a DAKO Autostainer. The expression of ETS-1 in stromal TILs was analysed on an Olympus 41 microscope. The IHS score was calculated and correlated with clinical and pathological parameters, as well as disease-free survival (DFS) and overall survival (OS). RESULTS: In almost all patients (95%), some expression of ETS-1 in TILs was found. A moderate/high score of ETS-1 correlated with larger tumour size and higher histological grade, high proliferation index and low progesterone receptors (PgR). The patients with moderate/high ETS-1 expression in TILs had shorter DFS than patients with weak/negative ETS-1 expression. CONCLUSION: In invasive breast cancer NOS, expression of ETS-1 in TILs is an adverse prognostic factor.

Sign in / Sign up

Export Citation Format

Share Document